Search results for "Infarction"

showing 10 items of 1208 documents

Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal t…

2008

Risk stratification of patients with acute chest pain, non-diagnostic electrocardiogram and normal troponin (ACPneg) remains a challenge, partly because no standardized set of biomarkers with prognostic ability has been identified in this population. Lymphopenia has been associated with atherosclerosis progression and adverse outcomes in cardiovascular diseases; although its prognostic value in ACPneg is unknown. We sought to determine the relationship between the lymphocyte count obtained in the Emergency Department (ED) and the risk of the long-term all-cause mortality or myocardial infarction (MI) in patients with ACPneg.We analyzed 1030 consecutive patients admitted with ACPneg in our i…

Malemedicine.medical_specialtyAcute coronary syndromeChest Painmedicine.medical_treatmentPopulationMyocardial InfarctionRevascularizationDiagnosis DifferentialElectrocardiographyInternal medicinemedicineHumansMyocardial infarctionLymphocyte CounteducationSurvival analysisAgededucation.field_of_studybiologybusiness.industryVascular diseaseMiddle Agedmedicine.diseaseTroponinTroponinSurgerybiology.proteinFemaleMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessEmergency Service HospitalBiomarkersAtherosclerosis
researchProduct

Effect of invasive treatment on prognosis in non-ST-segment elevation acute coronary syndrome with or without systolic dysfunction.

2010

Introduction and objectives. Few data are available on the use of invasive treatment in patients with non-STsegment elevation acute coronary syndrome (NSTEACS) and systolic dysfunction. The aim of this study was to determine the effect of invasive treatment on the prognosis of patients with NSTEACS, with or without systolic dysfunction. Methods. The study included 972 consecutive patients admitted for NSTEACS (i.e. ST-segment depression or an elevated troponin-I level). Systolic dysfunction was defined as an ejection fraction <50% on transthoracic echocardiography. The primary long-term endpoint was death or myocardial infarction. The effect of invasive treatment on prognosis was evaluated …

Malemedicine.medical_specialtyAcute coronary syndromeEjection fractionbusiness.industrySystolemedicine.medical_treatmentHazard ratioGeneral MedicineRevascularizationmedicine.diseasePrognosisInternal medicineCardiologyClinical endpointMyocardial RevascularizationMedicineST segmentHumansFemaleMyocardial infarctionSystoleAcute Coronary SyndromebusinessAgedRevista espanola de cardiologia
researchProduct

Mitral Regurgitation and Prognosis After Non-ST-Segment Elevation Myocardial Infarction in Very Old Patients.

2019

Background/Objetctives: Mitral regurgitation (MR)after an acute coronary syndrome is associated with a poor prognosis. However,the prognostic impact of MR in elderly patients with non-ST-segment elevation myocardialinfarction (NSTEMI) has not been well addressed. Design: Prospective registry. Setting And Participants: The multicenter LONGEVO-SCA prospective registry included 532 unselected NSTEMI patients aged ≥80 years. Measurements: MR was quantified using echocardiography during admission in 497 patients. They were classified in two groups: significant (moderate or severe) or not significant MR (absent or mild). We evaluated the impact of MR status on mortality or readmission at 6 months…

Malemedicine.medical_specialtyAcute coronary syndromeEnfermedad cardiovascularAnciano030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineST segmentHumans030212 general & internal medicineMyocardial infarctionHospital MortalityProspective StudiesRegistriesNon-ST Elevated Myocardial InfarctionKillip classProportional Hazards ModelsAged 80 and overEjection fractionbusiness.industryHazard ratioMitral Valve InsufficiencyLength of Staymedicine.diseasePrognosisConfidence intervalGeriatríaBlood pressureEchocardiographyCardiologyVálvulas cardíacasFemaleGeriatrics and GerontologyInfarto de miocardiobusinessJournal of the American Geriatrics Society
researchProduct

Statin Treatment and Prognosis of Elderly Patients Discharged after Non-ST Segment Elevation Acute Coronary Syndrome

2019

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Statins are recommended for secondary prevention. Our aims were to describe the proportion of very elderly patients receiving statins after non-ST segment elevation acute coronary syndrome (NST-ACS) and to determine the prognostic implications of statins use. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; This prospective registry was performed in 44 hospitals that included patients ≥80 years discharged after a NST-ACS from April 2016 to September 2016. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We included 523 patients, the mean age was 84.2 ± 4.0 years and 200 patients (38.2%) were women. Previous statin treatment was recorded in 282 p…

Malemedicine.medical_specialtyAcute coronary syndromeFrail ElderlyAncianoEnfermedad cardiovascularComorbidity030204 cardiovascular system & hematologyTratamiento médico03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineEnfermos cardíacosmedicineHumansST segmentPharmacology (medical)Prospective StudiesRegistriesAcute Coronary SyndromeNon-ST Elevated Myocardial InfarctionAged 80 and overLdl cholesterolSecondary preventionbusiness.industryMean ageCholesterol LDLStatin treatmentPrognosismedicine.diseaseComorbidityPatient DischargechemistrySpain030220 oncology & carcinogenesisLow-density lipoproteinFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAncianosFollow-Up StudiesCardiology
researchProduct

Usefulness of Clinical Data and Biomarkers for the Identification of Frailty After Acute Coronary Syndromes

2015

Abstract Background Frailty predicts mortality after acute coronary syndrome (ACS). The standard frailty scales, such as the Fried score, consist of a variety of questionnaires and physical tests. Our aim was to investigate easily available clinical data and blood markers to predict frailty at discharge, in elderly patients after ACS. Methods A total of 342 patients older than 65 years, survivors after ACS, were included. A high number of clinical variables were collected. In addition, blood markers potentially linked to frailty and related to the processes of inflammation, coagulation, hormonal dysregulation, nutrition, renal dysfunction, and heart dysfunction were determined. Frailty was …

Malemedicine.medical_specialtyAcute coronary syndromeFrail ElderlyMyocardial InfarctionComorbidityDiseaseCohort StudiesRisk FactorsInternal medicineVitamin D and neurologyHumansMedicineMyocardial infarctionAcute Coronary SyndromeCystatin CVitamin DGeriatric AssessmentAgedAged 80 and overbusiness.industryPrognosismedicine.diseaseComorbidityPatient DischargeSurgeryPatient Outcome AssessmentHeart failureHemoglobinometryBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesCohort studyCanadian Journal of Cardiology
researchProduct

Early determination of homocysteine levels in acute coronary syndromes, is it an independent prognostic factor?

2004

Abstract Introduction Increased concentrations of homocysteine (tHcy) are considered a potentially modifiable risk factor for coronary heart disease. The relationship between plasma homocysteine and prognosis has been less well studied. The aim of this study was to examine a possible relationship between the homocysteine levels in admission and all cause mortality in subjects presenting with non-ST segment elevation (NSTE) acute coronary syndrome. Methods We studied 854 patients with suspected NSTE acute coronary syndrome admitted consecutively to our institution, tHcy was determined at a median of 3 days from enrolment and was analyzed in tertiles together with classical risk factors and o…

Malemedicine.medical_specialtyAcute coronary syndromeHomocysteineMyocardial InfarctionCoronary Diseasechemistry.chemical_compoundInternal medicinemedicineClinical endpointHumansRisk factorHomocysteineAgedCreatinineAnalysis of Variancebiologybusiness.industryAcute-phase proteinmedicine.diseasePrognosisTroponinSurvival AnalysisSurgerychemistrySpainHeart failureCardiologybiology.proteinLinear ModelsFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct

Homocysteine and long-term recurrent infarction following an acute coronary syndrome.

2021

En Cardiology Journal. Gdańsk (Polonia) : Via Medica. Vol. 28, n. 4 (01 jul. 2021), pp. 598-606. ISSN 1897-5593. e-ISSN 1898-018X. Este artículo se encuentra disponible en la siguiente URL: https://journals.viamedica.pl/cardiology_journal/article/view/CJ.a2020.0170/52602 En este artículo de investigación también participan: Maria Marco, Teresa García-Ballester, Begoña Zorio, Eduardo Núñez, Francisco J. Chorro, Juan Sanchis y Julio Núñez. Background: There are no well-established predictors of recurrent ischemic coronary events after an acute coronary syndrome (ACS). Higher levels of homocysteine have been reported to be associated with an increased atherosclerotic burden. The primary endpoi…

Malemedicine.medical_specialtyAcute coronary syndromeHomocysteinemedicine.medical_treatmentCoronary heart disease - Risk factors.Infarto de miocardio - Factores de riesgo.Enfermedad coronaria - Factores de riesgo.InfarctionClinical CardiologyRevascularizationCoronary artery diseasechemistry.chemical_compoundInterquartile rangeRisk FactorsInternal medicineMyocardial infarction - Risk factors.medicineHumansMyocardial infarctionAcute Coronary SyndromeHomocysteineAgedacute coronary syndrome coronary artery disease homocysteine recurrent myocardial infarction risk factorsCardiovascular system - Diseases - Risk factors.Framingham Risk Scorebusiness.industryEnfermedades cardiovasculares - Factores de riesgo.General Medicinemedicine.diseaseHospitalizationchemistryCardiologyST Elevation Myocardial InfarctionCardiology and Cardiovascular MedicinebusinessCardiology journal
researchProduct

Influence of Comorbid Conditions on One-Year Outcomes in Non–ST-Segment Elevation Acute Coronary Syndrome

2011

To investigate comorbid conditions with prognostic influence in non-ST-segment elevation acute coronary syndrome (NSTEACS).The study group consisted of a derivation cohort of 1017 patients (admitted from October 1, 2002, through October 1, 2008) and an external validation cohort of 652 patients (admitted from February 1, 2006, through September 30, 2009). Comorbid conditions, including risk factors and components of the Charlson comorbidity index (ChCI) and coronary artery disease-specific index, were recorded. The main outcome was one-year mortality.During follow-up, 103 patients died. After adjusting for variables associated with NSTEACS characteristics (base model), 5 comorbid conditions…

Malemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionComorbidityRisk AssessmentCoronary artery diseaseVentricular Dysfunction LeftInternal medicinemedicineHumansMyocardial infarctionProspective StudiesAcute Coronary SyndromeAgedAged 80 and overbusiness.industryST elevationMortality rateHazard ratioStroke VolumeGeneral MedicineMiddle Agedmedicine.diseasePrognosisComorbiditySurvival AnalysisConfidence intervalSurgeryMultivariate AnalysisCardiologyOriginal ArticleFemalebusiness
researchProduct

Resistin, acute coronary syndrome and prognosis results from the AtheroGene study

2006

Resistin, an adipocyte and macrophage derived cytokine, causes insulin resistance and glucose intolerance. We investigated the impact of resistin as a diagnostic marker in patients with acute coronary syndrome and its prognostic value for future cardiovascular events.Resistin levels were determined in 1153 patients with stable angina (SAP), 380 patients with unstable angina, 278 patients with non-ST-elevation myocardial infarction (NSTEMI) and 111 patients with ST-elevation myocardial infarction (STEMI). All patients have been followed up for a median follow-up of 2.6 years. During follow-up, 70 patients died from cardiovascular causes.Compared to SAP, resistin levels (5.1 ng/mL in SAP) wer…

Malemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionCoronary DiseaseAngina PectorisCoronary artery diseaseImpaired glucose toleranceAnginaElectrocardiographyRisk FactorsInternal medicineHumansMedicineResistinAngina Unstablecardiovascular diseasesMyocardial infarctionRisk factorAgedbusiness.industryUnstable anginaSyndromeMiddle AgedPrognosismedicine.diseaseLipidsSurgeryAcute DiseaseCardiologyFemaleResistinInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersAtherosclerosis
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct